Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Sharp Therapeutics's retained earnings for the quarter that ended in Dec. 2025 was C$-35.95 Mil.
Sharp Therapeutics's quarterly retained earnings
declined
from Jun. 2025 (C$-30.86 Mil) to Sep. 2025 (C$-32.70 Mil) and
declined
from Sep. 2025 (C$-32.70 Mil) to Dec. 2025 (C$-35.95 Mil).
Sharp Therapeutics's annual retained earnings
declined
from Dec. 2023 (C$-22.30 Mil) to Dec. 2024 (C$-28.33 Mil) and
declined
from Dec. 2024 (C$-28.33 Mil) to Dec. 2025 (C$-35.95 Mil).
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Sharp Therapeutics Retained Earnings Historical Data
* Premium members only.
The historical data trend for Sharp Therapeutics's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
What does a Retained Earnings of C$-35.95 Mil mean?
Sharp Therapeutics (TSXV:SHRX) has a Retained Earnings of C$-35.95 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Sharp Therapeutics and its competitors.
Is Sharp Therapeutics' Retained Earnings too high?
Sharp Therapeutics' current Retained Earnings is C$-35.95 Mil. Overall, Sharp Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Retained Earnings compare to VRTX and REGN?
Sharp Therapeutics' Retained Earnings of C$-35.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Sharp Therapeutics and its competitors. Sharp Therapeutics's current Retained Earnings is C$-35.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current Retained Earnings of C$-35.95 Mil. The current Retained Earnings is C$-35.95 Mil. Sharp Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current Retained Earnings is C$-35.95 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
14GF Score
Get the complete analysis for TSXV:SHRX
Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:SHRX has been successfully added to your 
